1. Home
  2. IDE vs VYGR Comparison

IDE vs VYGR Comparison

Compare IDE & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.53

Market Cap

206.7M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.81

Market Cap

236.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
VYGR
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.7M
236.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
IDE
VYGR
Price
$13.53
$3.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
53.9K
542.3K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$34.04
Revenue Next Year
N/A
$7.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.40
$2.65
52 Week High
$14.30
$5.55

Technical Indicators

Market Signals
Indicator
IDE
VYGR
Relative Strength Index (RSI) 59.19 43.17
Support Level $13.23 $3.72
Resistance Level $13.52 $3.85
Average True Range (ATR) 0.29 0.19
MACD 0.05 -0.00
Stochastic Oscillator 74.49 19.55

Price Performance

Historical Comparison
IDE
VYGR

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: